Results 11 to 20 of about 19,474 (223)

GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells

OncoImmunology, 2020
Expression of the disialoganglioside GD2 has been identified as a marker antigen associated with a breast cancer stem-like cell (BCSC) phenotype. Here, we report on the evaluation of GD2 as a BCSC-specific target antigen for immunotherapy. GD2 expression
Christian M. Seitz, Sarah Schroeder, Philipp Knopf, Ann-Christin Krahl, Jana Hau, Sabine Schleicher, Manuela Martella, Leticia Quintanilla-Martinez, Manfred Kneilling, Bernd Pichler, Peter Lang, Daniel Atar, Karin Schilbach, Rupert Handgretinger, Patrick Schlegel   +14 more
doaj   +2 more sources

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy

Journal of Immunology Research, 2017
Target selection is a key feature in cancer immunotherapy, a promising field in cancer research. In this respect, gangliosides, a broad family of structurally related glycolipids, were suggested as potential targets for cancer immunotherapy based on ...
Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, François Paris, Andras Heczey, Stéphane Birklé   +7 more
doaj   +2 more sources

Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia. [PDF]

PLoS ONE, 2014
Anti-GD2 antibody is a proven therapy for GD2-positive neuroblastoma. Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies.
Mickaël Terme, Mylène Dorvillius, Denis Cochonneau, Tanguy Chaumette, Wenhua Xiao, Mitchell B Diccianni, Jacques Barbet, Alice L Yu, François Paris, Linda S Sorkin, Stéphane Birklé   +10 more
doaj   +4 more sources

Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication [PDF]

Nature Medicine, 2022
The disialoganglioside GD2 is overexpressed on several solid tumors, and monoclonal antibodies targeting GD2 have substantially improved outcomes for children with high-risk neuroblastoma.
Johanna Theruvath, M. Menard, Benjamin A. H. Smith, Miles H. Linde, Garry L. Coles, G. N. Dalton, Wei Wu, L. Kiru, A. Delaidelli, E. Sotillo, John L. Silberstein, A. Geraghty, A. Banuelos, Molly Radosevich, Shaurya Dhingra, S. Heitzeneder, Aidan M Tousley, John Lattin, Peng Xu, Jing Huang, Nicole Nasholm, Andy L. He, Tracy C. Kuo, Emma Sangalang, J. Pons, Amira A. Barkal, Rachel E. Brewer, Kristopher D. Marjon, J. Vilches-Moure, Payton L. Marshall, Ricardo A. Fernandes, Michelle Monje, J. Cochran, Poul H. Sorensen, H. Daldrup-Link, I. Weissman, J. Sage, R. Majeti, C. Bertozzi, W. Weiss, C. Mackall, R. Majzner   +41 more
semanticscholar   +2 more sources

Neural Ganglioside GD2+ Cells Define a Subpopulation of Mesenchymal Stem Cells in Adult Murine Bone Marrow

Cellular Physiology and Biochemistry, 2013
Background/Aims: Due to the lack of specific markers, the isolation of pure mesenchymal stem cells (MSCs) from murine bone marrow remains an unsolved problem.
Jie Xu, WenJun Fan, Xi Xiang Tu, Teng Zhang, Zhi Jie Hou, Tao Guo, Xin Shu, Xi Luo, Yang Liu, Fei Peng, Chang Wang, LingZhi Xu, Han Zhou, Quentin Liu   +13 more
doaj   +2 more sources

GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma [PDF]

Clinical Cancer Research
Purpose: Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive ...
Roselia Ciccone, C. Quintarelli, A. Camera, Michele Pezzella, S. Caruso, S. Manni, Alessio Ottaviani, M. Guercio, F. del Bufalo, M. C. Quadraccia, D. Orlando, S. Di Cecca, M. Sinibaldi, Mariasole Aurigemma, L. Iaffaldano, Andrea Sarcinelli, M. L. D'Amore, Manuela Ceccarelli, F. Nazio, Veronica Marabitti, E. Giorda, M. Pezzullo, C. De Stefanis, A. Carai, S. Rossi, R. Alaggio, G. Del Baldo, M. Becilli, A. Mastronuzzi, B. De Angelis, F. Locatelli   +30 more
semanticscholar   +2 more sources

Prospects of anti-GD2 immunotherapy for retinoblastoma [PDF]

Frontiers in Immunology
Retinoblastoma is the most common type of eye tumor in infants and children. Current treatments for retinoblastoma include intravenous chemotherapy, intra-arterial chemotherapy, intravitreal chemotherapy, cryotherapy, radiotherapy, and surgery.
Xinlong Zhang, Wu-Lin You, Yun-Tao Wang, Rebeka Dejenie, Chenhao Wang, Yan Huang, Jingjing Li   +6 more
semanticscholar   +2 more sources

Ganglioside GD2 is a potential candidate marker for lung cancer stem cells [PDF]

Jichu yixue yu linchuang, 2023
Objective To explore the feasibility of ganglioside GD2 as a marker for lung cancer stem cells (LCSCs). Methods Cancer stem cells (CSCs) of lung cancer cell lines were enriched by spheroid culturing in vitro; The expression of stemness-related genes ...
LI Zhen, DUAN Zhaojun, LUO Yunping
doaj   +1 more source

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

Nature, 2022
Diffuse intrinsic pontine glioma (DIPG) and other H3K27M-mutated diffuse midline gliomas (DMGs) are universally lethal paediatric tumours of the central nervous system1.
R. Majzner, S. Ramakrishna, K. Yeom, Shabnum Patel, Harshini Chinnasamy, Liora M. Schultz, R. Richards, Li Jiang, Valentin V. Barsan, Rebecca Mancusi, A. Geraghty, Zinaida Good, A. Mochizuki, Shawn M. Gillespie, Angus M. S. Toland, Jasia Mahdi, Agnes Reschke, Esther H. Nie, Isabelle Chau, M. Rotiroti, Christopher W. Mount, C. Baggott, Sharon A. Mavroukakis, E. Egeler, J. Moon, C. Erickson, S. Green, Michael Kunicki, M. Fujimoto, Zachary J. Ehlinger, Warren D. Reynolds, Sreevidya Kurra, K. Warren, Snehit Prabhu, H. Vogel, L. Rasmussen, Timothy T. Cornell, S. Partap, P. Fisher, C. Campen, M. Filbin, G. Grant, B. Sahaf, K. Davis, S. Feldman, C. Mackall, Michelle Monje   +46 more
semanticscholar   +1 more source

Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy

Frontiers in Oncology, 2020
Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is
Bassel Nazha, Cengiz Inal, Taofeek K. Owonikoko   +2 more
doaj   +1 more source